摘要
Abstract
Hodgkin lymphoma(HL)is a highly curable B-cell malignancy,with its treatment paradigm shifting from tra-ditional chemotherapy toward a personalized"precision staging-dynamic adjustment"approach.In early-stage classical HL(CHL),the NIVAHL and BREACH trials demonstrated that combining immune checkpoint inhibitors(e.g.,nivolumab)or antibody-drug conjugates(e.g.,brentuximab vedotin,BV)with chemotherapy significantly improves complete response rates while reducing radiotherapy doses,without increasing secondary malignancy risks.For advanced-stage CHL,the SWOG S1826 trial established nivolumab-AVD as the new frontline standard,while the HD21 trial showed that the BrECADD regimen—by removing bleomycin and procarbazine—maintains efficacy(4-year PFS 94.3%)while reducing go-nadal toxicity to<5%,making it a preferred option for young patients.Elderly patients have seen groundbreaking progress,with nivolumab-AVD achieving a 25%improvement in 2-year PFS(89%vs.64%)over conventional regimens,and man-ageable immune-related toxicities.For relapsed/refractory HL,a stepwise strategy has emerged:PD-1 inhibitors or BV combined with chemotherapy,CD30-directed CAR-T cell therapy,and bispecific antibodies offer new options for multi-drug-resistant cases.Future research must aim to improve cure rates while achieving the dual objectives of minimizing treatment-related toxicity and optimizing long-term quality of life.关键词
霍奇金淋巴瘤/靶向治疗/免疫治疗Key words
Hodgkin lymphoma/Targeted therapy/Immunotherapy分类
医药卫生
